In silico design of a multivalent epitope vaccine against SARS-CoV-2 for Iranian populations
Research in Molecular Medicine
; 9(4):229-244, 2021.
Article
in English
| CAB Abstracts | ID: covidwho-2205940
ABSTRACT
Background:
Because of high genetic variation in human leukocyte antigen (HLA) alleles, epitope-based vaccines do not show equal efficacy in different human populations. Therefore, we proposed a multi-epitope vaccine against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) for Iranian populations. Materials andMethods:
For this purpose, the proteins without allergenicity and high antigenicity, as well as conservancy levels from SARS-CoV-2, were chosen for computational epitope mapping. The T-cell epitope mapping process was performed based on the most frequent human leukocyte antigen (HLA) alleles in Iran. The B- and T-cell epitopes were determined based on their allergenicity, antigenicity, and hemolytic potential. Then, the epitopes with acceptable features were subjected to the final construct. The screened epitopes were structured in the final vaccine sequence. The secondary and tertiary structures of the proposed vaccine were predicted, and its affinity to HLA-I, HLA-II, toll-like receptor (TLR)- 3, and TLR-4 were evaluated by the molecular docking method. Additionally, possible immune responses against the vaccine were predicted through immune simulation.
Full text:
Available
Collection:
Databases of international organizations
Database:
CAB Abstracts
Topics:
Vaccines
Language:
English
Journal:
Research in Molecular Medicine
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS